# Study of FlutiForm® Versus Fluticasone Plus Formoterol in Adult Subjects With Severe Asthma

> **NCT00734318** · PHASE3 · COMPLETED · sponsor: **Mundipharma Research Limited** · enrollment: 1667 (actual)

## Conditions studied

- Asthma, Bronchial

## Interventions

- **DRUG:** Flutiform 250/10 micrograms
- **DRUG:** Flutiform 50/5 micrograms
- **DRUG:** Flixotide pMDI 250 mcg + foradil pMDI 24 micrograms
- **DRUG:** Flixotide pMDI 250 micrograms

## Key facts

- **NCT ID:** NCT00734318
- **Lead sponsor:** Mundipharma Research Limited
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2008-09
- **Primary completion:** 2009-06
- **Final completion:** 2009-10
- **Target enrollment:** 1667 (ACTUAL)
- **Last updated:** 2018-10-24


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00734318

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00734318, "Study of FlutiForm® Versus Fluticasone Plus Formoterol in Adult Subjects With Severe Asthma". Retrieved via AI Analytics 2026-06-16 from https://api.ai-analytics.org/clinical/NCT00734318. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*